Janusz Jaworski Selected Research

Antirheumatic Agents (DMARD)

1/2019	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
6/2016	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janusz Jaworski Research Topics

Disease

8	Rheumatoid Arthritis 11/2022 - 02/2017
3	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2023 - 06/2016
1	Knee Fractures 01/2024
1	Body Weight (Weight, Body) 11/2023
1	Respiratory Sounds (Crackle) 01/2023
1	Psoriatic Arthritis 06/2016
1	Ankylosing Spondylitis 01/2016

Drug/Important Bio-Agent (IBA)

7	Biosimilar PharmaceuticalsIBA 11/2023 - 02/2017
4	Adalimumab (Humira)FDA Link 11/2022 - 01/2018
3	CT-P13IBA 01/2021 - 01/2016
2	CT-P17IBA 11/2022 - 01/2021
2	Antirheumatic Agents (DMARD)IBA 01/2019 - 06/2016
2	Infliximab (Remicade)FDA Link 02/2017 - 01/2016
1	Ustekinumab (CNTO 1275)FDA Link 11/2023
1	Doxycycline (Periostat)FDA LinkGeneric 01/2023
1	Prednisolone (Predate)FDA LinkGeneric 01/2023
1	Citric Acid (Citrate)FDA LinkGeneric 01/2021
1	CT-P10IBA 02/2019
1	Rituximab (Mabthera)FDA Link 02/2019
1	GP2015IBA 01/2019
1	Etanercept (Enbrel)FDA Link 01/2019
1	apremilastIBA 06/2016
1	Phosphodiesterase 4 InhibitorsIBA 06/2016

Therapy/Procedure

1	Osteotomy 01/2024
1	Therapeutics 06/2016